CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
December 2017—LabCorp and Cancer Genetics have signed agreements with Thermo Fisher Scientific to join the Next-Generation Sequencing Companion Dx Center of Excellence Program. Each laboratory will participate in oncology-focused clinical trials in collaboration with pharmaceutical companies and Thermo Fisher. The companies may also qualify for early access to Thermo Fisher’s pipeline of platforms and assays to assist with development of Oncomine-branded solutions for clinical and biopharma applications. CGI began offering in June the Oncomine Dx Target Test, an NGS-based test that simultaneously screens tumor samples for multiple biomarkers associated with three FDA-approved therapies for non-small cell lung cancer, and LabCorp will begin offering the test later this year.
In a separate announcement, the Thermo Scientific TSX Series of ultra-low temperature freezers, which are designed to reduce energy consumption while ensuring sample protection, have earned the U.S. Environmental Protection Agency’s Energy Star certification. Other Energy Star-certified ultra-low freezers from the company include the Thermo Scientific TSX, Forma 89000, Revco RLE, TLE, and the HeraFreeze HLE Series.
Thermo Fisher Scientific, 866-356-0354